Health Boards
Calcipotriol/betamethasone dipropionate ointment most commonly know as Dovobet / Daivobet / Taclonex is studied for effectiveness and safety in pediatric patients with mild to moderate plaque psoriasis.
Source: NO LINKS ALLOWED
More on Dovobet Dovobet Ointment
Quote:
Background:
Psoriasis in children has a significant negative impact on the quality of life (Qol) and effective treatment can improve this. The two-compound ointment calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g is an effective treatment option for moderate to severe psoriasis in adults.
Objectives:
To prospectively study the effectiveness and safety of calcipotriol/betamethasone dipropionate ointment in pediatric patients with mild to moderate plaque psoriasis in daily clinical practice and to investigate the influence on Qol.
Methods:
Data were obtained from a prospective longitudinal pediatric psoriasis registry, called Child-CAPTURE. Severity was assessed by the Psoriasis Area and Severity Index (PASI) and body surface area (BSA). The Children's Dermatology Life Quality Index (CDLQI) was used to assess Qol. Visual Analogue Scores (VAS) for pain and itch were used. For safety data the number of (serious) adverse events was recorded.
Results:
Seventy-three patients (mean age 10.8 years, range 3-18) were treated for a median time of 35.0 weeks (range 1.0-176.0). At week 12, mean PASI decreased 15.4% (from 5.2 to 4.4), BSA barely changed, and median CDLQI decreased significantly from 5.5 to 4.0. VAS pain and itch declined. At week 24, mean PASI decreased to 4.3 (17.3%). No related serious adverse events were observed.
Conclusions:
In this daily clinical practice study in pediatric psoriasis, calcipotriol/betamethasone dipropionate ointment initially improves mild to moderate psoriasis and then maintains its effect. In addition, it improves Qol, with few adverse events.
Source: NO LINKS ALLOWED
More on Dovobet Dovobet Ointment